CFO Exits Days After Q3 Loss as PacBio Turnaround Stumbles
PACB has more than doubled off its 52-week low of $1.07.
Summary
CFO Jim Gibson is stepping down, with Mark Van Oene named interim finance chief. The timing is awkward: it lands the same day PacBio reported a $37.8M Q3 loss on $40.6M revenue with gross margin down to 33%, and roughly three months after the company cut 2026 revenue guidance to $155M-$165M and pushed cash-flow breakeven out. Van Oene is already CEO, so he now holds both roles on an interim basis — thin bench at a company burning cash. Gibson had filed in early October to sell 661,815 shares under a pre-arranged 10b5-1 plan, a sale that settled around $2.06M. A finance chief leaving mid-turnaround, right after a weak quarter, raises questions about the credibility of the narrowed guidance and the restructuring plan. Watch for the 10-Q and any disclosure on the terms of Gibson's departure or a permanent CFO search.
At the time of this announcement, PACB was trading at $2.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $792.6M. The 52-week trading range was $1.07 to $3.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.